Nucala 100 MG/ML auto-injectorml
Ended Awarded
- Contract number
- SPE2DB26FNMND
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $1,893
Award facts
- Contract value 100% obligated
- $1,892.90 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a delivery order valued at $1,892.90 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Nucala 100 mg/ml auto-injector units. This firm fixed-price delivery order, issued on October 29, 2025, with an ultimate completion date of October 30, 2025, was awarded without a set-aside designation, reflecting DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. The contract contains no identified subcontractor relationships, with DMS Pharmaceutical Group serving as the prime contractor responsible for fulfilling the pharmaceutical supply requirement directly.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish regional prime vendor contractors supplying diverse pharmaceutical products to Department of Defense military healthcare facilities worldwide. The underlying IDC, designated SPE2DR and awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. DMS Pharmaceutical Group's established performance across numerous delivery orders for specialty pharmaceuticals, biologics, and medical consumables demonstrates its capability to support recurring DoD medical supply requirements globally.
Quick answers
Who was awarded contract SPE2DB26FNMND?
SPE2DB26FNMND was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 29, 2025.
How much is contract SPE2DB26FNMND worth?
The government has obligated $1,893 on SPE2DB26FNMND.
Is contract SPE2DB26FNMND an order under another contract?
Yes. SPE2DB26FNMND is a delivery order under SPE2DB25D9348, an indefinite delivery contract.
Was contract SPE2DB26FNMND competed?
The extent of competition for SPE2DB26FNMND was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award